MERCK KGAA

TILT Biotherapeutics presents Phase I data on TILT-123, an intravenous oncolytic adenovirus therapy for advanced solid cancers, at ESMO 2024, demonstrating safety and tumor transduction.

Orbis Research report analyzes Biotechnology Contract Manufacturing Market, detailing market segmentations, product analysis, R&D developments, supply chain dynamics, and expert opinions. Special focus on geopolitical impacts, key players, and strategic insights.

The Cell Based Assays Market is projected to grow from USD 20.42 Billion in 2023 to USD 39.23 Billion by 2031, driven by pharmaceutical R&D, technological advancements, personalized medicine, and reduced animal testing. Key challenges include high costs, complexity, and technical limitations. Trends include 3D cell culture, AI integration, precision medicine, and immuno-oncology. North America leads the market, followed by Asia Pacific and Europe.

The In Vitro Diagnostics (IVD) Quality Control Market is projected to grow from USD 686.78 Million in 2023 to USD 1150.36 Million by 2031, at a CAGR of 6.66%. The market is driven by increasing demand for accurate diagnostic tests, technological advancements, and the adoption of point-of-care testing. Key challenges include the complexity of diagnostic technologies, regulatory compliance, and variability in test performance. The market is segmented by products & services (quality control products, data management solutions) and application (infectious diseases, oncology, cardiology, autoimmune disorders). North America dominates the market, followed by Europe and Asia Pacific.

The Glycomics/Glycobiology Market is projected to grow from USD 1.43 Billion in 2024 to USD 5.25 Billion by 2031, driven by advancements in biomedical research, technological innovations, and rising healthcare expenditure. Key challenges include the complexity of glycan structures and high R&D costs. The market is segmented by product type, application, technology, and geography, with North America leading and Asia Pacific showing rapid growth. Major players include Thermo Fisher Scientific, Danaher Corporation, and Merck KGaA.

The cell counting market is projected to reach $15.3 billion by 2028 with an 8.9% CAGR, driven by precision medicine, regenerative medicine, point-of-care testing, and stem cell research. Key players include Thermo Fisher Scientific, Merck KGaA, PerkinElmer, and Bio-Rad Laboratories. Market segments include consumables, products, applications, and end-users.

The Global Biological Buffers Market is projected to grow from USD 741.69 million in 2023 to USD 1,524.14 million by 2033, at a CAGR of 7.47%. Biological buffers control pH levels, maintain stability, and aid cellular functions, crucial in medicine, research, and diagnostics. Key drivers include rising research activity, increased demand for blood and plasma, and technological advancements. The phosphate type segment is expected to dominate, and the research institution segment will hold the largest market share. Europe is forecasted to lead the market, while Asia Pacific will exhibit the highest CAGR.

The cell separation market is expected to grow from USD 9.1 billion in 2023 to USD 22.3 billion by 2033, driven by tech advancements, biopharmaceutical demand, and increased investments. Key techniques include centrifugation and MACS, with North America leading and Asia-Pacific expected to grow fastest. Notable developments include Terumo's partnership with CiRA Foundation for iPS cell automation and significant investments in healthcare technologies.

Roche's fenebrutinib achieved a mid-stage win in RMS, showing near-total elimination of disease activity, while Sanofi's tolebrutinib had mixed results, missing primary endpoints in two Phase III studies but succeeding in a third, delaying disability progression in progressive MS. Both drugs face safety concerns, particularly liver injury, which will be a key focus at upcoming presentations. Despite mixed results, tolebrutinib is expected to generate $2.6 billion in sales by 2030, while fenebrutinib is projected to reach $810 million.

The Global Biotechnology Market, valued at USD 1,094.6 Billion in 2024, is projected to reach USD 2772.7 Billion by 2032, with a CAGR of 14.2%. The market report includes detailed analysis, key players, and segments such as applications and technologies, with regional assessments covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.